Literature DB >> 25316321

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

Adrián LLerena1, Maria Eugenia G Naranjo, Fernanda Rodrigues-Soares, Eva M Penas-LLedó, Humberto Fariñas, Eduardo Tarazona-Santos.   

Abstract

INTRODUCTION: The frequency of CYP2D6 alleles, related to either a lack of or increased enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM), can vary across ethnic groups and hence across geographic regions. AREAS COVERED: Worldwide original research papers on CYP2D6 allelic frequencies, metabolic phenotype frequencies measured with a probe drug, and/or genotype frequencies that studied > 50 healthy volunteers, were included in analyses to describe the distributions of alleles, phenotypes predicted from genotypes (predicted poor metabolizers [gPMs], predicted ultrarapid metabolizers [gUMs]) and metabolic phenotypes (mPMs, mUMs) across ethnic groups and geographic regions. The analysis included 44,572 individuals studied in 172 original research papers. EXPERT OPINION: As of today, Africa and Asia are under-represented in this area relative to the total number of their inhabitants, so that further studies in these regions are warranted. The CYP2D6*4 allele frequency was higher in Caucasians, CYP2D6*10 in East Asians, CYP2D6*41 and duplication/multiplication of active alleles in Middle Easterns, CYP2D6*17 in Black Africans and CYP2D6*29 in African Americans, than in other ethnic groups. Overall, gPMs and mPMs are more frequent among Caucasians, and gUMs among Middle Easterns and Ethiopians. However, mUMs could not be evaluated because only two studies were found presenting this information. Further studies including mUMs are thus warranted. There is a correspondence between gPMs and mPMs, but the few studies of mUMs meant that their relationship with gUMs could not be demonstrated. Finally, evolutionary aspects of the CYP2D6 allele distribution appear to support the Great Human Expansion model.

Entities:  

Keywords:  CYP2D6; CYP2D6*10; CYP2D6*17; CYP2D6*29; CYP2D6*4; CYP2D6*41; ethnicity; poor metabolizers; population pharmacogenetics; ultrarapid metabolizers

Mesh:

Substances:

Year:  2014        PMID: 25316321     DOI: 10.1517/17425255.2014.964204

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  40 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

Review 3.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

4.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

Review 5.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

6.  A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.

Authors:  M E Moretti; D F Lato; H Berger; G Koren; S Ito; W J Ungar
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

7.  Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.

Authors:  Ivan Skadrić; Oliver Stojković
Journal:  Int J Legal Med       Date:  2019-12-20       Impact factor: 2.686

8.  Codeine use among children in the United States: a nationally representative study from 1996 to 2013.

Authors:  Margaret J Livingstone; Cornelius B Groenewald; Jennifer A Rabbitts; Tonya M Palermo
Journal:  Paediatr Anaesth       Date:  2016-10-25       Impact factor: 2.556

9.  The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.

Authors:  Maria Stella Calafato; Isabelle Austin-Zimmerman; Johan H Thygesen; Mani Sairam; Antonio Metastasio; Louise Marston; Francisco Abad-Santos; Anjali Bhat; Jasmine Harju-Seppänen; Haritz Irizar; Eirini Zartaloudi; Elvira Bramon
Journal:  Pharmacogenomics J       Date:  2020-02-04       Impact factor: 3.550

10.  High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Authors:  G Moya; P Dorado; V Ferreiro; M E G Naranjo; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-04-12       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.